Epithalon

Also known as Epitalon, Ala-Glu-Asp-Gly, Epithalamin analogue.

Research / investigational listing only. This compound is not available for consumer purchase from Cellular Sequence and must not be confused with shop products.

Research / investigational compoundThis compound does not have an established approved therapeutic dosing schedule. Doses below describe those reported in published scientific research and should not be interpreted as a treatment recommendation.

At-a-glance profile

Classification: Synthetic tetrapeptide (pineal / telomere research — research only)
Approval status: Research only · Not approved for human use
Research status: Investigational tetrapeptide. Not TGA/FDA/EMA approved as a longevity drug.
Molecular formula: Insufficient reliable evidence identified.
Molecular weight: Insufficient reliable evidence identified.
Sequence: Ala-Glu-Asp-Gly (AEDG tetrapeptide; also spelled epitalon)
Primary biological target: Proposed telomerase / pineal peptide signalling. Mechanism not yet fully established.
Half-life: Insufficient reliable evidence identified.
Routes investigated: Experimental parenteral (Khavinson school literature)
Human evidence level: D — Primarily animal / preclinical evidence

What is it?

A research-only peptide associated with telomerase and ageing hypotheses. It is not an approved longevity medicine.

Synthetic tetrapeptide associated with pineal peptide research programmes.

Mechanism of action

Mechanism not yet fully established.

Proposed mechanism: epitalon has been reported to affect telomerase and geroprotective markers in experimental systems. Mechanism not yet fully established. Independent, modern registrational trials were not identified.

Unproven as a human longevity intervention.

What is it being studied for?

Ageing biology
E · Mechanistic / theoretical evidence only
Mechanistic/theoretical and regional experimental literature exceed the independent Phase 3 evidence base.^[1]

Investigational findings are not proven clinical benefits unless an authority has labelled that indication.

Evidence level

Overall human evidence grade: D · Primarily animal / preclinical evidence

Human research

Limited, largely non-ICH literature; not practice-changing.

Preclinical research

Animal, cell and in-vitro findings are listed separately from human effects.

Cell and animal ageing models; interpret cautiously.

Doses reported in published research

This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.

Doses reported in human studies

Insufficient reliable evidence identified.

Preclinical / animal study dosing

Insufficient reliable evidence identified.

Pharmacokinetics

Reliable ICH-standard human PK were not identified.

Safety

Insufficient reliable evidence identified.

Unknowns. Unknowns dominate.

Contraindications. Not for human use.

Regulatory status

Australia — TGA: Not approved.
United States — FDA: Not approved.
European Union — EMA: Not approved.

Citations

[1] Peptide geroprotection literature associated with AEDG / epitalon (regional experimental corpus)
Khavinson VKh et al. Peptide geroprotection literature associated with AEDG / epitalon (regional experimental corpus) Various experimental gerontology papers. 2003. PMID 14518447
PMID 14518447

For educational and research reference only. This page summarises published scientific literature and does not constitute medical advice, prescribing information or a recommendation to use an investigational compound. Research doses shown describe doses reported in published studies and are not personalised dosing instructions.

Last reviewed 2026-09-13. Research areas: Healthy Ageing · Compare peptides